Biology Reference
In-Depth Information
56. Nguyen T, Menocal EM, Harborth J, Fruehauf JH (2008) RNAi therapeutics: an update on
delivery. Curr Opin Mol Ther 10:158-167
57. de Fougerolles AR (2008) Delivery vehicles for small interfering RNA in vivo. Hum Gene
Ther 19:125-132
58. Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, Chorn N, Lin LS,
Bristol G, Boyd MP et al (2004) Anti-human immunodeficiency virus hematopoietic progeni-
tor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human
immunodeficiency virus type-1-infected patients. Hum Gene Ther 15:251-262
59. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari
J, Becker S, Thornton L et al (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in
autologous CD34(+) cells. Nat Med 15:285-292
60. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud
M, Abel U, Dal-Cortivo L, Caccavelli L et al (2009) Hematopoietic stem cell gene therapy
with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818-823
61. Dropulic B (2001) Lentivirus in the clinic. Mol Ther 4:511-512
62. Kambal A, Mitchell G, Cary W, Gruenloh W, Jung Y, Kalomoiris S, Nacey C, McGee J,
Lindsey M, Fury B et al (2011) Generation of HIV-1 resistant and functional macrophages
from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther 19:584-593
63. Muesing MA, Smith DH, Cabradilla CD, Benton CV, Lasky LA, Capon DJ (1985) Nucleic
acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature
313:450-458
64. Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B (2005) HIV-1 can escape from RNA
interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res
33:796-804
65. Westerhout EM, Berkhout B (2007) A systematic analysis of the effect of target RNA struc-
ture on RNA interference. Nucleic Acids Res 35:4322-4330
66. Watts JM, Dang KK, Gorelick RJ, Leonard CW, Bess JW Jr, Swanstrom R, Burch CL, Weeks
KM (2009) Architecture and secondary structure of an entire HIV-1 RNA genome. Nature
460:711-716
67. Low JT, Knoepfel SA, Watts JM, ter Brake O, Berkhout B, Weeks KM (2012) SHAPE-
directed discovery of potent shRNA inhibitors of HIV-1 Mol Ther: 20(4):820-828
68. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM (1997) Sustained expression of genes
delivered directly into liver and muscle by lentiviral vectors. Nat Genet 17:314-317
69. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B (2006) Silencing of HIV-1 with RNA
interference: a multiple shRNA approach. Mol Ther 14:883-892
70. von Eije KJ, Ter Brake O, Berkhout B (2009) Stringent testing identifies highly potent and
escape-proof anti-HIV short hairpin RNAs. J Gene Med 11:459-467
71. McIntyre GJ, Groneman JL, Yu YH, Jaramillo A, Shen S, Applegate TL (2009) 96 shRNAs
designed for maximal coverage of HIV-1 variants. Retrovirology 6:55
72. Jacque JM, Triques K, Stevenson M (2002) Modulation of HIV-1 replication by RNA inter-
ference. Nature 418:435-438
73. Chang LJ, Liu X, He J (2005) Lentiviral siRNAs targeting multiple highly conserved RNA
sequences of human immunodeficiency virus type 1. Gene Ther 12:1133-1144
74. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG,
Lieberman J, Shankar P, Sharp PA (2002) siRNA-directed inhibition of HIV-1 infection. Nat
Med 8:681-686
75. Park WS, Miyano-Kurosaki N, Hayafune M, Nakajima E, Matsuzaki T, Shimada F, Takaku
H (2002) Prevention of HIV-1 infection in human peripheral blood mononuclear cells by
specific RNA interference. Nucleic Acids Res 30:4830-4835
76. Berkhout B, Ter Brake O (2008) Towards an RNAi-based gene therapy. BIOforum Europe
4:35-37
77. Surabhi RM, Gaynor RB (2002) RNA interference directed against viral and cellular targets
inhibits human immunodeficiency virus type 1 replication. J Virol 76:12963-12973
Search WWH ::
Custom Search